Valuation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration) Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled, Ascending Repeated-Dose, Three-Arm Parallel Design ECG Study in Healthy Adult Subjects.

Trial Profile

Valuation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration) Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled, Ascending Repeated-Dose, Three-Arm Parallel Design ECG Study in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2011

At a glance

  • Drugs Moxifloxacin; Neramexane
  • Indications Alzheimer's disease; Bacterial infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 19 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top